Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AmgenCHIX:AMGD 89 Net Cash per Share is €-114.24 as of Mar. 2026. GuruFocus rates CHIX:AMGD with a GF Score™ of 89/100 and a GF Value™ of €276.86 (Fairly Valued). The stock has 8 warning signs investors should review. Among 259 Drug Manufacturers companies, Amgen ranks worse than 386100% on this metric.
The historical rank and industry rank for Amgen's Net Cash per Share or its related term are showing as below:
CHIX:AMGd's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.13 * Ranked among companies with meaningful Price-to-Net-Cash only.
Amgen (CHIX:AMGd) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Amgen Net Cash per Share Related Terms
Amgen Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Amgen's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMGD vs GILD, PFE, BMY: Net Cash per Share Comparison
For the Drug Manufacturers - General subindustry, Amgen's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Amgen's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Amgen's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amgen (CHIX:AMGD) has a Net Cash per Share of €-114.24 as of Mar. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Amgen and its competitors. According to the industry distribution chart, Amgen ranks #999999 out of 259 companies in the Drug Manufacturers industry.
Is Amgen's Net Cash per Share too high?
Amgen's current Net Cash per Share is €-114.24. Based on the distribution chart, Amgen ranks #999999 out of 259 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Amgen has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Amgen's Net Cash per Share compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #999999 out of 259 companies for Net Cash per Share. This places Amgen in the lower half of its industry. The industry median Net Cash per Share is 8.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.13, based on 259 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current Net Cash per Share is €-114.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Fairly Valued. The stock's GF Value™ is €276.86, compared to a current price of €285.00 — trading 2.9% above its estimated fair value. The current Net Cash per Share is €-114.24. Amgen's overall GF Score™ is 89/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current Net Cash per Share is €-114.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be overvalued.
The current stock price of €285.00 is trading 2.9% above its estimated GF Value™ of €276.86.
GuruFocus considers Amgen to be Fairly Valued.
Key valuation signals for CHIX:AMGD:
Net Cash per Share: €-114.24
GF Value™: €276.86 vs. price of €285.00 (2.9% above fair value)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
89GF Score
Get the complete analysis for CHIX:AMGD
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 
